FDA approves cabozantinib (Cabometyx) for treatment of patients with previously treated radioactive iodine-refractory differentiated thyroid cancer differentiated thyroid cancer

Approx 5% to 15% of cases are resistant to radioiodine treatment, with life expectancy of 3 to 5 years. Trial evaluating Cabometyx in this population met 1of the 2 primary endpoints of significant improvement versus placebo in progression-free survival (11.0 vs.1.9 months).

SPS commentary:

Final of phase 3 COSMIC-311 pivotal trial (n=258) have been presented at conference. At a median follow-up of 10.1 months, Cabometyx reduced the risk of disease progression or death versus placebo (HR 0.22; 96% CI, 0.15–0.32) in the intent-to-treat (ITT) population.

PharmaTimes

Resource links:

Conference report: final result from phase 3 COSMIC-311 study